专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08642643B2 CXCR2 antagonists 有权
标题翻译： CXCR2拮抗剂
公开(公告)号：US08642643B2
公开(公告)日：2014-02-04
申请号：US12337970
申请日：2008-12-18
申请人： Stephanie Hachtel , Juergen Dedio , Josef Pernerstorfer , Stephen Shimshock , Carolina Lanter , Raymond Kosley
发明人： Stephanie Hachtel , Juergen Dedio , Josef Pernerstorfer , Stephen Shimshock , Carolina Lanter , Raymond Kosley
IPC分类号： A01N43/02 , A61K31/38 , A01N43/12 , A01N43/40 , A61K31/44 , C07D333/00 , C07D409/02 , C07D409/00 , C07D411/00
CPC分类号： C07C235/66 , C07C2602/08 , C07C2602/10 , C07D213/30 , C07D277/64 , C07D333/54
摘要： The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及其中R1，R2，A，B，X和Y具有权利要求中所示含义的式I化合物和/或其药学上可接受的盐和/或其前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

2. 发明授权

US08980938B2 CXCR2 inhibitors 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US08980938B2
公开(公告)日：2015-03-17
申请号：US12337980
申请日：2008-12-18
申请人： Stephanie Hachtel , Juergen Dedio , Josef Pernerstorfer , Stephen Shimshock , Carolina Lanter
发明人： Stephanie Hachtel , Juergen Dedio , Josef Pernerstorfer , Stephen Shimshock , Carolina Lanter
IPC分类号： A01N43/12 , A61K31/38 , A01N43/02 , C07D333/52 , C07D333/72 , C07D409/02 , C07D333/16 , C07C235/66 , C07D333/54
CPC分类号： C07D333/16 , C07C235/66 , C07C2601/14 , C07C2602/10 , C07D333/54
摘要： The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及其中R1，R2，A，B，X和Y具有权利要求中所示含义的式I化合物和/或其药学上可接受的盐和/或其前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

3. 发明授权

US08552033B2 Inhibitors of CXCR2 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US08552033B2
公开(公告)日：2013-10-08
申请号：US12337107
申请日：2008-12-17
申请人： Stephanie Hachtel , Juergen Dedio , Stephen Shimshock , Carolina Lanter
发明人： Stephanie Hachtel , Juergen Dedio , Stephen Shimshock , Carolina Lanter
IPC分类号： A61K31/4535 , A61K31/428 , A61K31/381 , A61K31/382 , A61K31/351 , A61K31/341 , A61K31/195 , A61K31/196 , C07D409/12 , C07D277/64 , C07D335/02 , C07D333/38 , C07D307/24 , C07D309/14 , C07C57/62 , C07C61/40
CPC分类号： C07D277/64 , C07C235/66 , C07C2601/10 , C07D307/24 , C07D309/14 , C07D335/02 , C07D409/12 , C07D417/12
摘要： The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及其中R1，R2，X，A，B和Y1至Y4具有权利要求中所示含义的式I化合物和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

4. 发明申请

US20080090854A1 CXCR2 INHIBITORS 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US20080090854A1
公开(公告)日：2008-04-17
申请号：US11771958
申请日：2007-06-29
申请人： Stephanie HACHTEL , Juergen DEDIO , Holger HEITSCH , Werngard Czechtizky , Sven Grueneberg , Stephen Shimshock , Raymond Kosley , Carolina Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
发明人： Stephanie HACHTEL , Juergen DEDIO , Holger HEITSCH , Werngard Czechtizky , Sven Grueneberg , Stephen Shimshock , Raymond Kosley , Carolina Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
IPC分类号： A61K31/195 , A61K31/381 , A61K31/4245 , A61K31/428 , A61K31/44 , A61K31/4436 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/505 , A61P11/00 , A61P17/00 , A61P25/00 , A61P29/00 , A61P9/00 , C07C235/66 , C07D211/60 , C07D213/56 , C07D215/14 , C07D239/36 , C07D271/00 , C07D277/64 , C07D333/50 , C07D409/12
CPC分类号： C07D213/68 , C07D207/325 , C07D213/30 , C07D213/65 , C07D213/69 , C07D215/14 , C07D217/26 , C07D231/12 , C07D233/64 , C07D249/06 , C07D249/08 , C07D249/18 , C07D261/08 , C07D263/32 , C07D271/12 , C07D277/24 , C07D277/64 , C07D307/42 , C07D317/54 , C07D319/20 , C07D333/56 , C07D333/70 , C07D409/12 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及式I化合物：其中R1，R2，X，A，B，D和Y1至Y4具有权利要求中所示的含义，和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

5. 发明授权

US08501981B2 CXCR2 inhibitors 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US08501981B2
公开(公告)日：2013-08-06
申请号：US12337040
申请日：2008-12-17
申请人： Stephanie Hachtel , Juergen Dedio , Elisabeth DeFossa , Sven Grueneberg , Holger Heitsch , William Bock , Charlie Chen , Raymond Kosley , Chung-Yi Kung , Marcel Patek , Rosy Sher , Stephen Shimshock , Aleksandra Weichsel
发明人： Stephanie Hachtel , Juergen Dedio , Elisabeth DeFossa , Sven Grueneberg , Holger Heitsch , William Bock , Charlie Chen , Raymond Kosley , Chung-Yi Kung , Marcel Patek , Rosy Sher , Stephen Shimshock , Aleksandra Weichsel
IPC分类号： C07C229/00 , C07C69/76 , C07C61/00 , A01N37/12
CPC分类号： C07D333/16 , C07C233/83 , C07C235/66 , C07C237/48 , C07C311/29 , C07C2601/04 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07D213/65 , C07D215/26 , C07D233/60 , C07D295/088 , C07D307/24 , C07D333/64
摘要： The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及其中R 1，R 2，X，A，B，Z和Y 1至Y 4具有权利要求中所示含义的式I化合物和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

6. 发明申请

US20070265278A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS 审中-公开
标题翻译： 2-PHENYL-INDOLES作为PROSTAGLANDIN D2受体拮抗剂
公开(公告)号：US20070265278A1
公开(公告)日：2007-11-15
申请号：US11782890
申请日：2007-07-25
申请人： Keith HARRIS , Hans-Jochen Lang , Rose Mathew , Stephen Shimshock , Thaddeus Nieduzak , Sharon Jackson , Zhaoxia Yang , Kenneth Bordeau
发明人： Keith HARRIS , Hans-Jochen Lang , Rose Mathew , Stephen Shimshock , Thaddeus Nieduzak , Sharon Jackson , Zhaoxia Yang , Kenneth Bordeau
IPC分类号： A61K31/404 , A61K31/4245 , A61K31/435 , A61K31/4453 , A61K31/47 , A61K31/495 , A61P1/04 , A61P37/08 , A61P9/00 , C07D209/04 , C07D271/113 , C07D401/12
CPC分类号： C07D209/12 , C07D209/18 , C07D209/22 , C07D209/24 , C07D405/12 , C07D413/06
摘要： The present invention is directed to a compound of Formula (XVI): (please replace Formula (I) with Formula (XVI) as shown below) wherein R, R2, R3, R4, R5, R6, R7 and n are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (XVI) in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (XVI).
摘要翻译：本发明涉及式（ⅩⅥ）化合物：（如下所示，用式（ⅩⅥ）表示的式（I）表示）其中R，R 2，R 3， R 4，R 4，R 5，R 6，R 7和n如本文所定义，或其药学上可接受的盐，水合物或溶剂化物，其药学上可接受的前药，或药学上可接受的盐，水合物或溶剂化物，药物组合物，其包含药学上有效量的根据式（XVI）的一种或多种化合物与药学上可接受的载体混合，治疗患有PGD2介导的病症的患者的方法，包括但不限于过敏性疾病（例如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身肥大细胞增多症，伴有系统性肥大细胞活化，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴有瘙痒的疾病（如特应性皮炎和荨麻疹），伴随瘙痒的行为（如刮伤和殴打）而产生的疾病（如白内障，视网膜脱离，炎症，感染和睡眠障碍），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向所述患者施用药学有效量的根据式（XVI）的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式